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There are two discrete forms of steatosis that may be found in patients infected with hepatitis C virus (HCV).  Metabolic 
steatosis can coexist with HCV, regardless of genotype, in patients with risk factors such as obesity, hyperlipidemia, and 
insulin resistance.  The second form of hepatic steatosis in HCV patients is a result of the direct cytopathic effect of 
genotype 3 viral infections.  There have been proposed mechanisms for this process but it remains elusive.  Both 
categories of steatosis tend to hasten the progression of liver fibrosis and therefore prompt recognition and management 
should be initiated in patients with HCV and steatosis.  The authors review the current understanding of the 
relationship between hepatitis C infection and hepatic steatosis and discuss future research directions. 
Key words: hepatitis C, obesity, metabolic syndrome, diabetes, steatosis, NAFLD, NASH 
1. Introduction 
The usual progression of liver disease in patients 
with hepatitis C (HCV) is a process of inflammation 
accompanied by periportal necrosis and fibrosis.  The 
inflammation that results from the virus causes 
stimulation of stellate cells which ultimately leads to the 
deposition of collagen which leads to fibrosis progression 
within the liver.  If this process is rapid and unhindered 
then the usual outcome is the development of cirrhosis 
which is the final irreversible stage characterized by 
parenchymal nodules with encircling fibrous septa.  The 
hepatitis C virus is not considered to directly injure the 
liver but it rather triggers an HCV-specific 
lymphoproliferation. Through profuse cytokine 
production and also a direct cytopathic effect, these T cells 
result in hepatocyte apoptosis. [1]   
Many patients with chronic HCV are also noted to 
have a degree of steatosis present on their liver biopsies.  
Hepatic steatosis is defined as excessive lipid 
accumulation within the hepatocyte cytoplasm and has 
been more recently recognized as a significant cause for 
cirrhosis in the United States. [2]  There are two forms of 
steatosis present in patients with hepatitis C, specifically 
metabolic steatosis and  HCV-induced steatosis.  Metabolic 
steatosis is a process which occurs in the setting of obesity, 
hyperlipidemia, and insulin resistance.  This form of 
steatosis is also similar to the type of fatty infiltration 
which occurs from excessive alcohol consumption.  
Metabolic steatosis is not triggered in anyway by the 
hepatitis C virus however the combination of this form of 
steatosis and the presence of HCV has been associated 
with a more rapid progression of fibrosis.  The other type 
of steatosis found in patients with HCV is fatty infiltration 
that is directly elicited by the virus.  Though the precise 
mechanism is not well known, HCV-induced steatosis is 
recognized as the sole route for a direct cytopathic effect 
by the hepatitis C virus.  This review will focus on the two 
different forms of steatosis and its implications on the 
natural history of HCV. 
2. Metabolic Steatosis 
The etiology for hepatic steatosis can be determined 
by the distribution and size of the lipid accumulation 
within the hepatocytes.  Microvesicular steatosis that is 
seen in Reye’s syndrome and Acute Fatty Liver Disease of 
Pregnancy occurs due to dysfunctions in β-oxidation of 
free fatty acids and this can result in acute liver failure. [3]  
On the other hand, macrovesicular steatosis is the 
histologic finding in patients with Non-alcoholic Fatty 
Liver Disease (NAFLD).  NAFLD is characterized by gross 
macrovesicular fatty change with lobular or portal 
inflammation in the absence of a significant alcohol 
history.  This disease is frequently under-recognized and 
is now identified as the most common cause of 
cryptogenic cirrhosis. [4]  NAFLD occurs in the setting of 
obesity, hyperlipidemia, and diabetes all of which is now 
accepted under one syndrome called the Metabolic 
Syndrome. 
The Metabolic Syndrome (also known as syndrome 
X, the deadly quartet, the insulin resistance syndrome, 
and the obesity dyslipidemia syndrome) consists of 
abdominal obesity leading to insulin resistance, 
hypertension, and hypertriglyceridemia and is now 
recognized as the major predisposition to hepatic 
steatosis. [5-6]  The most widely supported theory 
recognizes insulin resistance as the major mechanism in 
the pathogenesis of hepatic steatosis. [7-11]  In an autopsy 
report from 1990, investigators found that of 22 patients 
with histologically confirmed fatty liver disease, 20 were 
also obese and had diabetes mellitus. [12] 
The presumption that there is a causal relationship 
between the Metabolic Syndrome and disease progression 
in HCV makes sense given the connection between 
steatosis and necroinflammatory activity in patients with 
HCV. [13-14]  Previous studies have indicated that obesity 
is a risk factor independent of  elevated ALT levels which 
predict fibrosis progression.  A study from Spain found 
that there is a larger proportion of fast progressors and a 
lower proportion of slow progressors in patients with 
body mass index (BMI) levels of greater than 30 kg/m2. 
Int. J. Med. Sci. 2006, 3 54
[15]  Recognizing this risk factor may warrant weight loss 
in our obese patients just as much as alcohol abstinence in 
our patients with HCV.  A small study of 19 patients 
showed that a weight loss of only 5.9 kg and a reduction 
in BMI by only 2 kg/m2 may account for a significant 
reduction in both steatosis and fibrosis progression in 
patients with hepatitis C. [16]  Thus, our more motivated 
patients with hepatitis C absolutely deserve the extra 
means available for weight loss, not only for 
cardiovascular health but also to reduce the risk of fibrosis 
and ultimately cirrhosis. 
Patients with the metabolic syndrome have some 
degree of insulin resistance.  Diabetes was once thought to 
be an ailment secondary to the lack of insulin production 
but is now recognized as an illness of insulin resistance 
and resultant hyperinsulinemia.  First line therapy now 
specifically targets insulin-mediated glucose utilization in 
the liver and peripheral tissue. [17-18]  It has now been 
demonstrated that improvement occurs in both steatosis 
and the resultant inflammation by the use of insulin 
sensitizing agents. [19]  Therefore, utilization of these 
medications are becoming more and more necessary in 
our patients with non-alcoholic steatohepatitis and 
certainly in our patients with HCV and metabolic 
steatosis. 
3. HCV-Induced Steatosis 
The presence of steatosis on liver biopsy in patients 
with hepatitis C is more frequent when compared to other 
chronic liver diseases such as chronic hepatitis B and 
autoimmune hepatitis. [20]  Steatosis is also 2.5 times 
more prevalent in patients with HCV when compared to 
the general population. [21]  The macrovesicular steatosis 
present in patients with HCV is also distributed in the 
periportal areas rather than the centrilobular region which 
is more commonly seen in NAFLD. [22]  This all infers 
that the hepatitis C virus may be directly inducing 
steatosis in these patients rather than simply being an 
unrelated finding. 
It has been shown that HCV genotype 3 is 
independently associated with hepatocellular steatosis in 
patients with chronic hepatitis C. [23]  Furthermore, the 
severity of steatosis in these patients is directly related to 
the burden of the HCV RNA load.  This relationship 
between the HCV viral load and the magnitude of 
steatosis was not observed in other HCV genotypes. [24]  
It has also been noticed that the steatosis which was 
initially present in patients with genotype 3 infection 
resolves after a sustained virologic response is achieved 
through treatment with pegylated interferon-α and 
ribavirin. [25]  Not only does the steatosis resolve with 
eradication of the virus but it also recurs if relapse 
transpires.  All of these findings were only observed with 
the HCV genotype 3 virus and was not reproducible with 
other HCV genotypes.  These findings all point to the 
ability of the HCV genotype 3 virus to directly induce 
steatosis, although the mechanism still remains elusive. 
Thus, there seems to be two distinct forms of 
steatosis in patients with chronic hepatitis C.  Metabolic 
steatosis generally occurs in all genotypes of HCV 
infections and likely worsens the progression of HCV 
induced fibrosis.  Then there are those patients with 
genotype 3 infections who have a form of steatosis that is 
directly induced by the hepatitis C virus and which also 
resolves with successful treatment.  These two forms of 
steatosis can certainly coexist in patients with genotype 3 
infections with other underlying metabolic diseases.  In 
these patients, we would expect that the steatosis would 
only partially resolve with successful eradication of the 
virus and that the remaining fatty infiltration is a result of 
NAFLD. 
4. Mechanism of HCV-Induced Steatosis 
Most, if not all, studies to date have used HCV 
genotype 1 constructs in vitro, thus our current 
understanding of the process leading to lipid 
accumulation is limited.  However, putative mechanisms 
exist where the presence of a particular viral component 
leads to lipid accumulation within the hepatocyte.  HCV 
core protein has been studied at length in both cell 
cultures and in transgenic mice.  Intracellular lipid 
buildup seems to occur when the HCV core protein is 
strongly expressed. [26]  The core protein has been located 
at the surface of lipid droplets within the cytoplasm in cell 
cultures that are transfected  with HCV while absent in 
control cells. [27]   
HCV core protein may be interacting with 
apolipoprotein AII which is a major component of high-
density lipoproteins and this interaction may be causing 
hepatocellular steatosis. [28]  Other proposed mechanisms 
suggest an interaction between the core protein and 
retinoid X receptor α (RxRα) which is a transcriptional 
regulator that has many cellular functions, one of which is 
the metabolism of lipids. [29]  Other theories propose that 
the core protein induces oxidative stress within the 
mitochondria which leads to or contributes to lipid 
accumulation.  [30]  This notion was formulated due to the 
association between hepatic steatosis in transgenic mice 
and the presence of increased lipid peroxidation. [31]  All 
of these premises point to a complex interaction between 
the HCV core protein and other components of the 
hepatocyte which ultimately contributes to the onset of 
steatosis.  Though the exact mechanism remains elusive, it 
seems firmly established that the hepatitis C virus, in and 
of itself, can directly induce cytoplasmic lipid 
accumulation.  Further studies examining the genotype 3 
virus are warranted to further recognize the process 
involved in HCV-induced steatosis. 
5. Disease Progression 
It is difficult to ascertain whether HCV-induced 
steatosis and metabolic steatosis contribute equally to the 
overall disease progression in patients with hepatitis C.  
As discussed before, there have been many studies which 
have demonstrated a relationship between the severity of 
steatosis and the extent of fibrosis on liver biopsy 
specimens.  However, the majority of studies to date have 
not separated the two types of steatosis when examining 
its affects on fibrosis progression in HCV patients.  
Nonetheless, it has been generally accepted that either 
steatosis by itself aggravates fibrosis or the factors that are 
causing steatosis may be aggravating fibrosis. [32]  There 
has also been some suggestion that the two forms of 
steatosis may act synergistically to trigger severe 
advancement of fibrosis in patients with genotype 3 
infections. [32]  Overall, steatosis, whether metabolic or 
HCV induced, worsens the sequence of events leading to 
advanced fibrosis in patients with HCV and needs to be 
addressed when managing our patients with HCV.  
Ultimately, further studies are warranted to distinguish 
viral steatosis between metabolic steatosis and both of 
their effects on fibrosis progression in patients with HCV. 
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6. Conclusion 
All in all, there is a clinically significant relationship 
between HCV infection and hepatic steatosis.  Two forms 
of steatosis exist in our patients with HCV.  The first type 
of steatosis occurs secondary to metabolic factors namely 
alcohol use or the metabolic syndrome.  This form of 
steatosis is not initiated by the hepatitis C virus however it 
can very well increase the progression of fibrosis 
ultimately towards cirrhosis.  The other form of steatosis 
occurs as a direct result of the HCV genotype 3 virus 
through complex interactions between the HCV core 
protein and the hepatocyte, the knowledge of which 
remains to be fully unravelled.  This type of steatosis also 
very well causes more rapid progression of disease.  It is 
important to recognize the category of steatosis present in 
our patients with HCV in order to properly treat them.  
Those with metabolic steatosis warrant strict attention to 
weight loss and countering the effects of insulin resistance 
while focus on HCV eradication can be given to those 
with HCV-induced steatosis. 
7. Research Direction 
It is well established that there is an association 
between HCV and steatosis and the mechanisms behind 
this relationship are currently being unravelled.  In order 
to fully understand the intricate molecular processes 
involved in HCV genotype-3 induced hepatocellular 
steatosis, future studies need to analyze viral and 
metabolic steatosis as distinct groups.  Research should 
also continue to focus on therapies for insulin resistance 
and steatosis-induced fibrosis in chronic hepatitis C.  In 
order to devise specific therapies for HCV-induced 
steatosis, further investigation needs to be done on the 
complex derangements in lipid metabolism with focus on 
the genotype 3 virus. 
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